Mea Kākau: Gregory Harris
Lā O Ka Hana: 14 Apelila 2021
HōʻAno Hou I Ka Lā: 27 Okakopa 2024
Anonim
Mode of action of Saccharomyces boulardii CNCM I-745
Wikiō: Mode of action of Saccharomyces boulardii CNCM I-745

Anter

ʻO Saccharomyces boulardii kahi hū. Ua ʻike ʻia ma mua he ʻano ʻē aʻe o ka hū. I kēia manawa ua manaʻo ʻia he ʻāpana o Saccharomyces cerevisiae. Akā ʻokoʻa ʻo Saccharomyces boulardii mai nā ʻano ʻē aʻe o ka Saccharomyces cerevisiae i ʻike pinepine ʻia me ka hū a ka mea kahuʻai. Hoʻohana ʻia ʻo Saccharomyces boulardii i lāʻau lapaʻau.

Hoʻohana pinepine ʻia ʻo Saccharomyces boulardii no ka mālama ʻana a me ka pale ʻana i ka maʻi diarrhea, me nā ʻano infectious e like me ka rotaviral diarrhea i nā keiki. Loaʻa iā ia kahi hōʻike o ka hoʻohana no nā ʻano diarrhea ʻē aʻe, huehue, a me kahi maʻi maʻi digestive i hiki ke alakaʻi ʻia i ka maʻi ulcer.

ʻO ka maʻi Coronavirus 2019 (COVID-19): ʻAʻohe hōʻike maikaʻi e kākoʻo ai i ka hoʻohana ʻana iā Saccharomyces boulardii no COVID-19. E hāhai i nā koho nohona olakino a me nā ʻano hana pale i hōʻoia ʻia ma kahi.

Nā Laʻau Laʻau Kūlohelohe Kūlohelohe nā helu kūpono e pili ana i nā hōʻike ʻepekema e like me ka pālākiō e hiki mai ana: Ka maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi ʻole, ka maikaʻi ʻole, ka maikaʻi ʻole, a me ka lawa ʻole o nā hōʻike i ka helu.

Nā helu kūpono no SACCHAROMYCES BOULARDII penei:


Pili paha ia no ...

  • Pohā. Hōʻike ka noiʻi e hāʻawi ana i ka Saccharomyces boulardii i nā keiki me ka maʻi diarrhea hiki ke hoʻemi i ka lōʻihi o ka lōʻihi a hiki i ka 1 lā. Akā ʻo Saccharomyces boulardii me he mea lā ʻaʻole ʻoi aku ka maikaʻi ma mua o nā lāʻau maʻamau no ka maʻi diarrhea, e like me loperamide (Imodium).
  • Hoʻopilikia ʻia e ka rotavirus. ʻO ka hāʻawi ʻana iā Saccharomyces boulardii i nā pēpē a me nā keiki me ka maʻi diarrhea i hoʻokumu ʻia e rotavirus hiki ke hōʻemi i ka lōʻihi o ka palahalaha ma kahi o 1 lā.

E kūpono paha no ...

  • Huehue. Hōʻike ka noiʻi e lawe ana i ka Saccharomyces boulardii e ka waha e hoʻomaikaʻi ai i ka helehelena o ka huehue.
  • ʻO ka maʻi pākī i ka poʻe e lawe ana i nā antibiotic (diarrhea antibiotic-pili). Hōʻike ka hapanui o nā noiʻi e hiki i ka Saccharomyces boulardii ke pale aku i ka maʻi kōkō i nā mākua a me nā keiki e mālama ʻia me nā lāʻau ʻaloʻalo. No kēlā me kēia 9-13 mau mea maʻi i mālama ʻia me Saccharomyces boulardii i ka wā o ka mālama ʻana me nā lāʻau ʻalopika, e hoʻomohala kekahi mea liʻiliʻi loa i ka maʻi palaho e pili ana i nā antibiotic.
  • ʻO ka maʻi o ka gastrointestinal tract e nā bacteria i kapa ʻia ʻo Clostridium difficile. ʻO ka lawe ʻana iā Saccharomyces boulardii me nā antibiotic me he mea lā ke kōkua ʻana e pale aku iā Clostridium difficile-pili diarrhea mai ka hoʻi hou ʻana i ka poʻe me ka moʻolelo o ka hoʻi hou ʻana. ʻO ka lawe ʻana iā Saccharomyces boulardii me nā lāʻau ʻalopika pū kekahi e kōkua ai i ka pale ʻana i nā ʻāpana mua o Clostridium difficile-pili diarrhea. Akā ʻaʻole koi ka poʻe loea i ka hoʻohana ʻana iā Saccharomyces no ka pale ʻana i nā ʻāpana mua.
  • ʻO kahi maʻi maʻi digestive e hiki ai i nā ulcer (Helicobacter pylori a i ʻole H. pylori). ʻO ka lawe ʻana iā Saccharomyces boulardii e ka waha me ka maʻamau ʻo H. pylori lapaʻau e kōkua ai e mālama i kēia maʻi. Ma kahi o 12 mau kānaka e pono e mālama ʻia me nā Saccharomyces boulardii hou aʻe no hoʻokahi mea maʻi e noho maʻi ʻole ʻia e hoʻōla ʻia. ʻO ka lawe ʻana iā Saccharomyces boulardii kōkua pū kekahi i ka pale ʻana i nā hopena ʻē aʻe e like me ka maʻi diarrhea a me ka nausea e hana ʻia me ka maʻamau ʻo H. pylori. Kōkua paha kēia i ka poʻe e hoʻopau i kā lākou hana maʻamau no H. pylori.
  • Diarrhea i ka poʻe me ka maʻi HIV / AIDS. Lawe ʻia ka Saccharomyces boulardii e ka waha e hōʻemi i ka maʻi diarrhea e pili ana i ka maʻi HIV.
  • ʻO kahi maʻi ʻōpū nui i nā pēpē premature (nekrotizing enterocolitis a i ʻole NEC). Hōʻike ka hapanui o ka noiʻi ʻana i ka hāʻawi ʻana iā Saccharomyces boulardii i nā pēpē preterm e pale iā NEC.
  • ʻO ka maʻi diarrhea. Lawe ʻia ʻo Saccharomyces boulardii e ka waha e pale aku i ka maʻi diarrhea.

ʻAʻole kūpono paha no ...

  • Kino maʻi (sepsis). Hōʻike nā noiʻi e hāʻawi ana i ka hāʻawi ʻana iā Saccharomyces boulardii i nā pēpē preterm ʻaʻole e pale i ka sepsis.

ʻAʻole lawa nā hōʻike e hōʻike i ka pono no ...

  • An maʻiʻaʻai o na naʻau i ke kumu diarrhea (cholera). ʻAʻole maikaʻi ka hoʻomaikaʻi ʻana i nā hōʻailona cholera i ka Saccharomyces boulardii, ʻoiai ke hāʻawi ʻia me nā lāʻau maʻamau.
  • Nā mākau hoʻomanaʻo a me ka noʻonoʻo (function cognitive). Hōʻike ka noiʻi mua ʻana i ka lawe ʻana iā Saccharomyces boulardii ʻaʻole ia e kōkua i nā haumāna e hoʻomaikaʻi i nā hōʻike a hoʻēmi paha i ko lākou koʻikoʻi.
  • ʻO kahi ʻano maʻi maʻi ʻōpū (Crohn disease). ʻO ka lawe ʻana iā Saccharomyces boulardii me he mea lā e hōʻemi ana i ka nui o ka neʻe ʻana o ka ʻōpū i ka poʻe me ka maʻi Crohn. Hōʻike pū kekahi kahi noiʻi mua i ka lawe ʻana iā Saccharomyces boulardii me mesalamine hiki ke kōkua i ka poʻe me ka maʻi Crohn e noho lōʻihi. Akā ʻo ka lawe ʻana iā Saccharomyces boulardii wale nō ʻaʻole ia e kōkua i ka poʻe me ka maʻi Crohn e noho lōʻihi i ke kala.
  • ʻO Cystic fibrosis. Hōʻike ka noiʻi mua i ka lawe ʻana i ka Saccharomyces boulardii e ka waha ʻaʻole e hoʻemi i nā maʻi hū ma ka pūnaehana digestive o ka poʻe me ka cystic fibrosis.
  • Hewa puʻuwai. Hōʻike ka noiʻi mua i ka lawe ʻana iā Saccharomyces boulardii e hoʻomaikaʻi ai i ka hana puʻuwai i ka poʻe me ka puʻuwai ʻole.
  • Kolesterol kiʻekiʻe. Hōʻike ka noiʻi mua ʻaʻole ʻike ka Saccharomyces boulardii i nā pae kolesterol.
  • ʻO kahi maʻi lōʻihi lōʻihi o nā ʻōpū nui e hōʻeha i ka ʻeha o ka ʻōpū (irritable bowel syndrome or IBS). Hōʻike ka noiʻi e lawe i ka Saccharomyces boulardii e hoʻomaikaʻi i ka maikaʻi o ke ola i ka poʻe me ka diarrhea-predominant a i ʻole ʻano ʻano IBS. Akā ʻaʻole paha ʻo Saccharomyces boulardii e hoʻomaikaʻi i ka hapanui o nā hōʻailona IBS e like me ka ʻeha o ka ʻōpū, ka wikiwiki, a me ka momona.
  • ʻO ka maʻi o nā ʻōpū e nā parasites. Hōʻike ka noiʻi mua i ka lawe ʻana i ka Saccharomyces boulardii e ka waha a me nā lāʻau ʻalopika e hoʻemi ana i ka maʻi diarrhea a me ka ʻeha o ka ʻōpū i ka poʻe me nā maʻi amoeba.
  • Yellowing o ka ʻili i nā pēpē (jaundice neonatal). Hoʻoulu kekahi mau pēpē i ka jaundice ma hope o ka hānau ʻana ma muli o ke kiʻekiʻe o ka pae bilirubin. ʻO ka hāʻawi ʻana iā Saccharomyces boulardii i nā pēpē manawa e pale paha i ka jaundice a hoʻēmi i ka pono no ka phototherapy i kahi helu liʻiliʻi o kēia mau pēpē. Akā ʻaʻole ʻike ʻia inā Saccharomyces boulardii e hoʻoliʻiliʻi i ka makaʻu o ka jaundice i nā pēpē makaʻu maka. ʻO ka hāʻawi ʻana iā Saccharomyces boulardii i nā pēpē me ka phototherapy ʻaʻole e hoʻohaʻahaʻa i nā pae bilirubin ʻoi aku ka maikaʻi ma mua o ka phototherapy wale nō.
  • Hānau ʻia nā pēpē i kaupaona ʻia ma lalo o 2500 gram (5 paona, 8 auneke). Ke hāʻawi nei i kahi Saccharomyces boulardii kumukanawai ma hope o ka hānau ʻana me he mea lā e hoʻomaikaʻi i ka loaʻa ʻana o ke kaupaona a me ka hānai ʻana i nā pēpē preterm me ke kaupaona hānau haʻahaʻa.
  • Ke ulu nui nei o nā koʻohune i loko o nā ʻōpū liʻiliʻi. Hōʻike ka noiʻi mua i ka hoʻohui ʻana iā Saccharomyces boulardii i ka mālama ʻana me nā lāʻau ʻalopika e hoʻemi ana i ka ulu ʻana o nā koʻohune ma mua o nā antibiotic wale nō.
  • ʻO kahi ʻano maʻi maʻi ʻōpū (ulcerative colitis). Hōʻike ka noiʻi mua i ka hoʻohui ʻana iā Saccharomyces boulardii i ka mesalamine therapy maʻamau hiki ke hōʻemi i nā hōʻailona i ka poʻe me ka colitis ulcerative ulcerative akahai.
  • ʻEha ʻo Canker.
  • Hū ka wela.
  • ʻO Hives.
  • Ka hoʻomanawanui ʻole ʻana i ka lactose.
  • Maʻi Lyme.
  • ʻO ka ʻehaʻeha o ka mākau ma muli o ka hoʻoikaika kino.
  • Nā maʻi maʻi urinary (UTIs).
  • Nā maʻi hū.
  • Nā kūlana ʻē aʻe.
Pono nā hōʻike hou aʻe e loiloi i ka Saccharomyces boulardii no kēia mau hoʻohana.

Kapa ʻia ʻo Saccharomyces boulardii he "probiotic," kahi meaola aloha e kōkua i ke kaua ʻana i nā meaola maʻi i loko o ka ʻōpū e like me ka bacteria a me ka hū.

Ke lawe ʻia e ka waha: ʻO Saccharomyces boulardii ʻo LIKELY SAFE no ka hapanui o nā mākua ke lawe ʻia e ka waha a hiki i 15 mau mahina. Hiki iā ia ke hana i ke kinoea i kekahi poʻe. Kākaʻikahi wale, kumu ia i nā maʻi fungal i hiki ke pālahalaha ma waena o ke koko i ke kino holoʻokoʻa (fungemia).

Nā mālama a me nā ʻōlelo aʻoaʻo kūikawā:

Hāpai a me ka hānai umauma: ʻAʻole lawa ka ʻike hilinaʻi e ʻike ai inā palekana ʻo Saccharomyces boulardii e hoʻohana ai ke hāpai a hānai umauma paha. Noho ma ka ʻaoʻao palekana a pale i ka hoʻohana.

Nā keiki: ʻO Saccharomyces boulardii ʻo SAFE MAU PONO no nā keiki ke lawe ʻia e ka waha kūpono. Eia nō naʻe, pono e loiloi i ka maʻi diarrhea i nā keiki e kekahi ʻoihana ola ma mua o ka hoʻohana ʻana iā Saccharomyces boulardii.

ʻElemakule: Loaʻa paha i ka ʻelemakule ka nui o ka makaʻu o ka maʻi fungal i ka wā e lawe ana iā Saccharomyces boulardii. Noho ma ka ʻaoʻao palekana a pale i ka hoʻohana.

ʻŌnaehana pale nawaliwali: Aia kekahi hopohopo no ka lawe ʻana i ka Saccharomyces boulardii i kumu e loaʻa ai ka fungemia, ʻo ia ke alo o ka hū i ke koko. ʻO ka helu maoli o nā hihia o Saccharomyces boulardii-pili fungemia paʻakikī e hoʻoholo. Eia nō naʻe, ʻoi aku ka nui o ka makaʻu no ka poʻe maʻi nui a i nāwaliwali paha i nā ʻōnaehana pale. Eia kekahi, ʻo ka poʻe me nā catheters, nā mea e loaʻa ana ka hānai ʻana o ka paipu, a me nā mea e mālama ʻia me nā antibiotic he nui a i ʻole nā ​​antibiotic e hana ana ma nā ʻano maʻi āpau e like me ka makaʻu. I nā kumu he nui, ua loaʻa ka fungemia mai ka hoʻohaumia ʻana o ka catheter e ka ea, nā ʻilikai o ke kaiapuni, a i ʻole nā ​​lima i hoʻohaumia ʻia me Saccharomyces boulardii.

ʻAha pāhoʻo hū: Hiki i nā poʻe me nā maʻi hū ke hu i nā huahana i loaʻa iā Saccharomyces boulardii, a ʻōlelo maikaʻi ʻia e hōʻalo i kēia huahana.

Mea liʻiliʻi
E makaʻala me kēia hui pū.
Nā lāʻau no ka maʻi fungal (Antifungals)
ʻO Saccharomyces boulardii kahi fungus. ʻO nā lāʻau no nā maʻi fungal e kōkua i ka hōʻemi ʻana i ka fungus i loko a ma ke kino. Lawe iā Saccharomyces boulardii me nā lāʻau no ka maʻi fungal hiki ke hōʻemi i ka maikaʻi o Saccharomyces boulardii.
ʻO kekahi mau lāʻau no ka maʻi fungal e komo pū me fluconazole (Diflucan), caspofungin (Cancidas), itraconazole (Sporanox) amphotericin (Ambisome), a me nā mea ʻē aʻe.
ʻAʻole ʻike ʻia nā launa pū me nā mea kanu a me nā mea hoʻopili.
ʻAʻole ʻike ʻia nā launa me nā meaʻai.
Ua aʻo ʻia nā mahele aʻe i ka noiʻi ʻepekema:

NA MAKAHIKI

E KA WAHI:
  • No ka maʻi palahēhē i ka poʻe e lawe ana i nā antibiotic (diarrhea antibiotic-pili): 250-500 mg o Saccharomyces boulardii i lawe ʻia i 2-4 mau manawa i kēlā me kēia lā a hiki i 2 mau pule e hoʻohana pinepine ʻia. I ka hapanui o nā hihia, ʻaʻole i ʻoi aku ka nui o nā koina o kēlā me kēia lā i ka 1000 mg i kēlā me kēia lā.
  • No ka maʻi o ka gastrointestinal tract e nā bacteria i kapa ʻia ʻo Clostridium difficile: No ka pale ʻana i ka hoʻi hou ʻana, 500 mg o Saccharomyces boulardii ʻelua mau manawa i kēlā me kēia lā no 4 mau pule me ka lāʻau antibiotic i hoʻohana ʻia.
  • No kahi maʻi maʻi digestive e hiki ai i nā ulcer (Helicobacter pylori a i ʻole H. pylori): 500-1000 mg o Saccharomyces boulardii i kēlā me kēia lā no 1-4 mau pule e hoʻohana pinepine ʻia.
  • No ka maʻi diarrhea i ka poʻe me HIV / AIDS: 3 gram o Saccharomyces boulardii i kēlā me kēia lā.
  • No ka diarrhea huakaʻi: 250-1000 mg o Saccharomyces boulardii i kēlā me kēia lā no 1 mahina.
KEIKI

E KA WAHI:
  • No ka maʻi palahēhē i ka poʻe e lawe ana i nā antibiotic (diarrhea antibiotic-pili): 250 mg o Saccharomyces boulardii i hoʻokahi manawa a i ʻole ʻelua mau manawa i kēlā me kēia lā no ka lōʻihi o nā antibiotic i hoʻohana ʻia.
  • No ka pehu: No ka mālama ʻana i ka maʻi pākī nui, 250 mg o Saccharomyces boulardii hoʻokahi a ʻelua mau manawa paha i kēlā me kēia lā a i ʻole 10 biliona mau kolone e hana ana i hoʻokahi manawa i kēlā me kēia lā no 5 mau lā i hoʻohana ʻia. No ka mālama ʻana i ka maʻi palahō mau, 1750 biliona a i 175 trillion mau ʻāpana koloni o Saccharomyces boulardii ʻelua mau manawa i kēlā me kēia lā no 5 mau lā i hoʻohana ʻia. No ka pale ʻana i ka maʻi diarrhea i ka poʻe e loaʻa ana ka hānai Tube, hoʻohana ʻia he 500 mg o Saccharomyces boulardii ʻehā mau manawa i kēlā me kēia lā.
  • No ka maʻi diarrhea i hoʻokumu ʻia e rotavirus: 200-250 mg o Saccharomyces boulardii ʻelua mau manawa i kēlā me kēia lā no 5 mau lā i hoʻohana ʻia.
  • No kahi maʻi ʻōpū nui i nā pēpē premature (necrotizing enterocolitis a i ʻole NEC): 100-200 mg / kg Saccharomyces boulardii i kēlā me kēia lā, e hoʻomaka ana i ka pule mua ma hope o ka hānau ʻana.
Probiotic, Probiotique, Saccharomyces, Saccharomyces Boulardii CNCM I-745, Saccharomyces Boulardii HANSEN CBS 5926, Saccharomyces Boulardii Lyo CNCM I-745, Saccharomyces Boulardius, Saccharomyces Cerevisiae Boulardii, Saccharomyces Cerevisiaeia Cerevisiae HANSEN CBS 5926, Saccharomyces cerevisiae var boulardii, S. Boulardii, SCB.

E aʻo hou aʻe ai pehea i kākau ʻia ai kēia ʻatikala, e ʻoluʻolu e ʻike i ka Nā Laʻau Laʻau Kūlohelohe Kūlohelohe ʻano hana.


  1. Florez ID, Veroniki AA, Al Khalifah R, et al. Hoʻohālikelike ka maikaʻi a me ka palekana o nā hana no ka diarrhea nui a me ka gastroenteritis i nā keiki: He loiloi ʻōnaehana a me nā meta-analysis o ka pūnaewele. PLoS Hoʻokahi. 2018; 13: e0207701. Nānā kiʻi ʻole.
  2. Harnett JE, Pyne DB, McKune AJ, Penm J, Pumpa KL. Hāʻawi ka Probiotic supplementation i nā loli maikaʻi i ka ʻehaʻeha a me ka maikaʻi o ka hiamoe i nā mea pāʻani pīpī. ʻO J Sci Med Sport. 2020: S1440-244030737-4. Nānā kiʻi ʻole.
  3. ʻO Gao X, Wang Y, Shi L, Feng W, Yi K. Ka hopena a me ka palekana o Saccharomyces boulardii no neonatal necrotizing enterocolitis i nā pēpē mua: He loiloi ʻōnaehana a me nā meta-analysis. J Trop Pediatr. 2020: fmaa022. Nānā kiʻi ʻole.
  4. Mourey F, Sureja V, Kheni D, et al. ʻO kahi multicenter, randomized, double-blind, placebo-kāohi hoʻokolohua o Saccharomyces boulardii i nā pēpē a me nā keiki me ka maʻi nui diarrhea. Pediatr Infect Dis J. 2020; 39: e347-e351. Nānā kiʻi ʻole.
  5. Karbownik MS, Kr & eogon; czy & nacute; ska J, Kwarta P, et al. Ka hopena o ka supplementation me Saccharomyces boulardii ma ka hana hoʻokolohua a me nā pilikia e pili ana i nā haumāna olakino olakino: ʻO ka hoʻokolohua hoʻokolohua, makapō makapō, kahi placebo. Nutrients. 2020; 12: 1469. Nānā kiʻi ʻole.
  6. Zhou BG, Chen LX, Li B, Wan LY, Ai YW. ʻO Saccharomyces boulardii ma ke ʻano he adjuvant therapy no Helicobacter pylori eradication: kahi ʻōnaehana loiloi a me nā meta-analysis me ka hoʻokolokolo ʻana me ka hoʻokolokolo ʻana. Helicobacter. 2019; 24: e12651. Nānā kiʻi ʻole.
  7. Szajewska H, ​​Kolodziej M, Zalewski BM. Nānā ʻōnaehana me ka meta-analysis: Saccharomyces boulardii no ka mālama ʻana i ka gastroenteritis nui i nā keiki-kahi hoʻomaikaʻi hou 2020. ʻO Aliment Pharmacol Ther. 2020. E nānā abstract.
  8. Seddik H, Boutallaka H, ​​Elkoti I, et al. ʻO Saccharomyces boulardii CNCM I-745 a me ke kaʻina hoʻomau no ka maʻi Helicobacter pylori: kahi hoʻāʻo ʻana, kahi hoʻokolohua hamama. ʻO Eur J Clin Pharmacol. 2019; 75: 639-645. Nānā kiʻi ʻole.
  9. García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Ka hopena o Saccharomyces boulardii a me Metronidazole no ka ulu nui ʻana o nā koʻohune liʻiliʻi liʻiliʻi i ka Systemic Sclerosis. ʻO Dis Dis Sci. 2019. Nānā i ka abstract.
  10. McDonald LC, Gerding DN, Johnson S, et al. ʻAhahui Infectious Diseases o ʻAmelika. Nā kulekele hana lapaʻau no ka maʻi Clostridium difficile i ka poʻe mākua a me nā keiki: 2017 hōʻano e ka Infectious Diseases Society of America (IDSA) a me ka Society of Healthcare Epidemiology of America (SHEA). Nā maʻi maʻi maʻi 2018; 66: e1-e48.
  11. Xu L, Wang Y, Wang Y, et al. ʻO ka hoʻāʻo makapō makapō makapō e pili ana i ka ulu ʻana a me ka hoʻomanawanui hānai ʻana me Saccharomyces boulardii CNCM I-745 i nā pēpē preterm hānai ʻia. J Pediatr (Rio J). 2016; 92: 296-301. Nānā kiʻi ʻole.
  12. Sheele J, Cartowski J, Dart A, et al. Saccharomyces boulardii a me bismuth subsalicylate ma ke ʻano he hana haʻahaʻa e hoʻemi i ka lōʻihi a me ke koʻikoʻi o ke kolera. ʻO ke olakino Pathog Glob. 2015; 109: 275-82. Nānā kiʻi ʻole.
  13. ʻO Ryan JJ, Hanes DA, Schafer MB, Mikolai J, Zwickey H. Ka hopena o ka Probiotic Saccharomyces boulardii ma Cholesterol a me Lipoprotein Particle i nā Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study. J Hoʻohui Hou Med. 2015; 21: 288-93. Nānā kiʻi ʻole.
  14. Flatley EA, Wilde AM, Nailor MD. Saccharomyces boulardii no ka pale ʻana i ka maʻi ʻo Clostridium difficile maʻi maʻi. ʻO J Gastrointestin Liver Dis. 2015; 24: 21-4. Nānā kiʻi ʻole.
  15. Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii e pale aku ai i ka maʻi palahū e pili ana i ka Antibiotic: He Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infect Dis. 2016; 3: ofw011. Nānā kiʻi ʻole.
  16. Dinleyici EC, Kara A, Dalgic N, et al. Saccharomyces boulardii CNCM I-745 hoʻoliʻiliʻi i ka lōʻihi o ka palahī, ka lōʻihi o ka mālama ulia pōpilikia a me ka noho haukapila i nā keiki me ka maʻi nui. Pōmaikaʻi i nā Microbes. 2015; 6: 415-21. Nānā kiʻi ʻole.
  17. ʻO Dauby N. Nā Pilikia o Saccharomyces boulardii-i loaʻa Probiotics no ka pale ʻana i ka maʻi Clostridium difficile i ka ʻelemakule. Gastroenterology. 2017; 153: 1450-1451. Nānā kiʻi ʻole.
  18. Cottrell J, Koenig K, Perfekt R, Hofmann R; ʻO Loperamide-Simethicone Acute Diarrhea Pūʻulu Haʻawina. Hoʻohālikelike o ʻelua ʻano o ka Loperamide-Simethicone a me kahi Probiotic Yeast (Saccharomyces boulardii) i ka mālama ʻana i ka maʻi hē nui i nā mākua: kahi hoʻokolohua hoʻokolohua non-haʻahaʻa haʻahaʻa. Nā Laʻau R D. 2015; 15: 363-73. Nānā kiʻi ʻole.
  19. Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. ʻO ka Probiotic therapy me Saccharomyces boulardii no nā mea maʻi puʻuwai puʻuwai: kahi hoʻokolohua pailaka, makapō makapō, makapo placebo-kāohi ʻia. Int J Cardiol. 2015; 179: 348-50. Nānā kiʻi ʻole.
  20. Carstensen JW, Chehri M, Schønning K, et al. Hoʻohana o prophylactic Saccharomyces boulardii e pale aku ai i ka maʻi Clostridium difficile i nā mea maʻi i hoʻopaʻa ʻia i ka haukapila. ʻO Eur J Clin Microbiol Infect Dis. 2018; 37: 1431-1439. Nānā kiʻi ʻole.
  21. Asmat S, Shaukat F, Asmat R, Bakhat HFSG, Asmat TM. Hoʻohālikelike Efficacy Clinical o Saccharomyces Boulardii a me Lactic Acid ma ke ʻano he Probiotics i loko o ka Diarrhea Pediatric Acute. ʻO J Coll Nā Kauka Surg Pak. 2018; 28: 214-217. Nānā kiʻi ʻole.
  22. Remenova T, Morand O, Amato D, Chadha-Boreham H, Tsurutani S, Marquardt T. A blind-blind, randomized, placebo-control trial Study the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmokinetics of miglustat. ʻO Orphanet J Rare Dis 2015; 10: 81. Nānā kiʻi ʻole.
  23. ʻO Suganthi V, Das AG. Ke kuleana o Saccharomyces boulardii i ka hoʻemi ʻana i ka hyperbilirubinemia neonatal. ʻO J Clin Diagn Res 2016; 10: SC12-SC15. Nānā kiʻi ʻole.
  24. Riaz M, Alam S, Malik A, Ali SM. Ka maikaʻi a me ka palekana o Saccharomyces boulardii i ka maʻi kōkō o ka wā ʻōpio: kahi ʻōlua makapō i hoʻokolokolo ʻia i hoʻokolokolo ʻia. Nūhou J Pediatr 2012; 79: 478-82. Nānā kiʻi ʻole.
  25. - Corrêa NB, Penna FJ, Lima FM, Nicoli JR, Filho LA. ʻO ka mālama ʻana i ka maʻi kōkō me Saccharomyces boulardii i nā pēpē. ʻO J Pediatr Gastroenterol Nutr 2011; 53: 497-501. Nānā kiʻi ʻole.
  26. Cohen SH, Gerding DN, Johnson S, et al. ʻO ka Society no Epidemiology Ola Ola o ʻAmelika; ʻAhahui Infectious Diseases o ʻAmelika. Nā ʻōkuhi hoʻomaʻamaʻa lapaʻau no ka maʻi Clostridium difficile i ka poʻe mākua: 2010 update e ke kaiāulu no ke olakino epidemiology o ʻAmelika (SHEA) a me nā maʻi maʻi maʻi ʻo ʻAmelika (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55. Nānā kiʻi ʻole.
  27. Goldenberg JZ, Ma SS, Saxton JD, et al. ʻO Probiotics no ka pale ʻana i ka maʻi maʻi Clostridium difficile-pili i ka poʻe mākua a me nā keiki. ʻO Cochrane Database Syst Rev. 2013;: CD006095. Nānā kiʻi ʻole.
  28. Lau CS, Chamberlain RS. Kūpono nā Probiotics i ka pale ʻana iā Clostridium difficile-pili diarrhea: kahi ʻōnaehana loiloi a me nā meta-analysis. ʻO Int J Gen Med. 2016; 9: 27-37. Nānā kiʻi ʻole.
  29. Roy U, Jessani LG, Rudramurthy SM, et al. ʻEhiku mau hihia o Saccharomyces fungaemia e pili ana i ka hoʻohana probiotics. Mycoses 2017; 60: 375-380. Nānā kiʻi ʻole.
  30. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. ʻO Saccharomyces cerevisiae fungemia i kahi mea maʻi pediatric ma hope o ka mālama ʻana me nā probiotics. ʻO Rev Paul Pediatr 2017; 35: 361-4. Nānā kiʻi ʻole.
  31. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii no ka pale ʻana i ka maʻi diarrhea e pili ana i nā lāʻau antibiotic i nā mea maʻi i hōʻola ʻia i nā poʻe mākua: kahi kikowaena hoʻokahi, randomized, blind-blind, placebo-control trial. 'Am J Gastroenterol 2012; 107: 922-31. Nānā kiʻi ʻole.
  32. Martin IW, Tonner R, Trivedi J, et al. Saccharomyces boulardii probiotic-associate fungemia: ke nīnau nei i ka palekana o ka hoʻohana ʻana o kēia probiotic preventive. ʻIkepili Microbiol Infect Dis. 2017; 87: 286-8. Nānā kiʻi ʻole.
  33. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. ʻO kahi hoʻokolohua, makapō makapō, hoʻokolohua hoʻokolohua multicenter placebo o Saccharomyces boulardii i loko o ka maʻi hanu huhū: hopena i ka maikaʻi o ke ola. ʻO J Clin Gastroenterol. 2011; 45: 679-83. Nānā kiʻi ʻole.
  34. Atici S, Soysal A, Karadeniz Cerit K, et al. ʻO ka Saccharomyces e pili ana i ka Catheter cerevisiae Fungemia Ma hope o Saccharomyces boulardii Probiotic lapaʻau: I ke keiki i ka mālama mālama nui a me ka loiloi ʻana i nā puke. Med Mycol Case Rep. 2017; 15: 33-35. Nānā kiʻi ʻole.
  35. Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J. Saccharomyces cerevisiae var. boulardii fungemia ma hope o ka hoʻomaʻamaʻa probiotic. Med Mycol Case Rep. 2017; 18: 15-7. Nānā kiʻi ʻole.
  36. Chang HY, Chen JH, Chang JH, Lin HC, Lin CY, Peng CC. ʻO nā probiotics maha he mau probiotics ka mea i ʻoi aku ka maikaʻi o ka probiotics i ka pale ʻana i ka necrotizing enterocolitis a me ka make ʻana. PLoS Hoʻokahi. 2017; 12: e0171579. Nānā kiʻi ʻole.
  37. Blaabjerg S, Artzi DM, Aabenhus R. Probiotics no ka Prevent o Antibiotic-Associated Diarrhea i nā mea maʻi o waho-A Review Systematic a me Meta-Analysis. Nā Antibiotics (Basel). 2017; 6. Nānā kiʻi ʻole.
  38. Al Faleh K, Anabree J. Probiotics no ka pale ʻana i ka enterrotrotitis necrotizing i nā pēpē preterm. ʻO Cochrane Database Syst Rev. 2014;: CD005496. Nānā kiʻi ʻole.
  39. ʻO Das S, Gupta PK, Das RR. Ka maikaʻi a me ka palekana o Saccharomyces boulardii i ka Acute Rotavirus Diarrhea: Pālua makapō makapō Randomized Controlled Trial mai kahi ʻāina kūkulu. J Trop Pediatr. 2016; 62: 464-470. Nānā kiʻi ʻole.
  40. ʻO Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. ʻO nā Probiotics no ka pale ʻana i ka maʻi pākīpī pediatric-pili diarrhea. ʻO Cochrane Database Syst Rev. 2015;: CD004827. Nānā kiʻi ʻole.
  41. Feizizadeh S, Salehi-Abargouei A, Akbari V. Ka hoʻokō ʻana a me ka palekana o Saccharomyces boulardii no ka maʻi diarrhea. Pediatrics. 2014; 134: e176-191. Nānā kiʻi ʻole.
  42. Szajewska H, ​​Horvath A, Kolodziej M. Nānā ʻōnaehana me ka meta-analysis: Saccharomyces boulardii supplementation a me ka hoʻopau ʻana i ka maʻi Helicobacter pylori. ʻO Aliment Pharmacol Ther. 2015; 41: 1237-1245. Nānā kiʻi ʻole.
  43. ʻO Szajewska H, ​​Kolodziej M. Nānā ʻōnaehana me ka meta-analysis: Saccharomyces boulardii i ka pale ʻana i ka maʻi palahā - pili i ka diarrhea. ʻO Aliment Pharmacol Ther. 2015; 42: 793-801. Nānā kiʻi ʻole.
  44. ʻO Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic haʻalulu ma muli o Sacccaromyces boulardii. Med Mal Infect. 2016; 46: 104-105. Nānā kiʻi ʻole.
  45. ʻO Bafutto M, et al. ʻO ka mālama ʻana i ka maʻi ʻōpū o ka maʻi diarrhea-me ka mesalamine a me / a i ʻole Saccharomyces boulardii. ʻO Arq Gastroenterol. 2013; 50: 304-309. Nānā kiʻi ʻole.
  46. ʻO Bourreille A, et al. ʻAʻole hiki i ka Saccharomyces boulardii ke pale i ka hoʻi hou ʻana o ka maʻi o Crohn. ʻO Gastroenterol Hepatol. 2013; 11: 982-987.
  47. Serce O, Gursoy T, Ovali F, Karatekin G. Nā hopena o Saccaromyces boulardii ma ka neonatal hyperbilirubinemia: kahi hoʻāʻo i kaohi ʻia ʻana. Am J Perinatol. 2015; 30: 137-142. Nānā kiʻi ʻole.
  48. ʻO Videlock EJ, ʻo Cremonini F. Meta-analysis: probiotics i ka maʻi diarrhea-pili diarrhea. ʻO Aliment Pharmacol Ther. 2012; 35: 1355-69. Nānā kiʻi ʻole.
  49. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. ʻO Probiotics no ka pale a me ka mālama ʻana i nā maʻi diarrhea e pili ana i nā antibiotic: kahi loiloi ʻōnaehana a me nā meta-analysis. JAMA. 2012 9; 307: 1959-69. Nānā kiʻi ʻole.
  50. Elmer GW, Moyer KA, Vega R, a me et al. ʻO ka loiloi ʻana o Saccharomyces boulardii no nā mea maʻi me ka maʻi diarrhea hoʻomau e pili ana i ka maʻi HIV a me nā mea manawaleʻa olakino e loaʻa ana nā antifungals. Microecology Ther 1995; 25: 23-31.
  51. ʻO Potts L, Lewis SJ, a me Barry R. Hoʻohālikelike ʻia kahi placebo makapō makapō i ka hiki o Saccharomyces boulardii e pale aku i nā maʻi kūpilikiʻi e pili ana i nā lāʻau ʻaloʻalo [abstract]. ʻO Gut 1996; 38 (sup 1): A61.
  52. ʻO Bleichner G lāua ʻo Blehaut H. Saccharomyces boulardii kaohi i ka maʻi diarrhea i nā mea maʻi pūpū maʻi maʻi nui. ʻO kahi multicenter, randomized, double-blind placebo-kontrol trial [abstract]. ʻO Clin Nutr 1994; 13 Hōʻawi 1:10.
  53. Maupas JL, Champemont P, a me Delforge M. [Hoʻomaʻamaʻa i ka maʻi hanu huhū me Saccharomyces boulardii - kahi makapō makapō, kahi aʻo ʻana o ka placebo i kāohi ʻia]. Médisin et Chirurgie Digestives 1983; 12: 77-79.
  54. Saint-Marc T, Blehaut H, Musial C, a me et al. [ʻO ka maʻi diarrhea e pili ana i ka maʻi AIDS: kahi hoʻāʻo makapō makapō ʻelua o Saccharomyces boulardii]. Semaine Des Hopitaux 1995; 71 (23-24): 735-741.
  55. McFarland LV, Surawicz C, Greenberg R, a me et al. ʻO Saccharomyces boulardii a me ka vancomycin lāʻau kiʻekiʻe e mālama i ka maʻi hou ʻo Clostridium difficile [abstract]. 'Am J Gastroenterol 1998; 93: 1694.
  56. Chouraqui JP, Dietsch J, Musial C, a me et al. Saccharomyces boulardii (SB) i ka mālama ʻana i ka maʻi kōkō o ke keiki ʻōpio: a study-blind-placebo kontroled study [abstract]. ʻO J Pediatr Gastroenterol Nutr 1995; 20: 463.
  57. ʻO Cetina-Sauri G a me Basto GS. Evaluacion terapeutica de Saccharomyces boulardii en ninos con diarrea aguda. Tribuna Med 1989; 56: 111-115.
  58. ʻO Adam J, Barret C, Barret-Bellet A, a me et al. Essais cliniques controles en double insu de lʻUltra-Levure Lyophilisee. ʻO Etude multicentrique par 25 medecins de 388 cas. ʻO Gaz Med Fr 1977; 84: 2072-2078.
  59. McFarland LV, SurawiczCM, Elmer GW, a me et al. ʻO ka loiloi Multivariate o ka pono olakino o kahi mea ola biotherapeutic, Saccharomyces boulardii no ka pale ʻana i nā maʻi maʻi e pili ana i nā antibiotic [abstract]. Am J Epidemiol 1993; 138: 649.
  60. ʻO Saint-Marc T, ʻo Rossello-Prats L, a me Touraine JL. [Ka hopena o Saccharomyces boulardii i ka mālama ʻana i ka maʻi pākī ʻo AIDS]. Ann Med Interne (Paris) 1991; 142: 64-65.
  61. Kirchhelle, A., Fruhwein, N., a me Toburen, D. [Hoʻomaʻamaʻa ʻana i ka maʻi palahū mau me S. boulardii i ka poʻe huakaʻi hoʻi. Nā hopena o kahi noiʻi prospective]. Fortschr Med 4-20-1996; 114: 136-140. Nānā kiʻi ʻole.
  62. Hānau ʻia, P., Lersch, C., Zimmerhackl, B., a me Classen, M. [The Saccharomyces boulardii therapy of HIV-associate diarrhea]. Dtsch Med Wochenschr 5-21-1993; 118: 765. Nānā kiʻi ʻole.
  63. Kollaritsch, H., Holst, H., Grobara, P., a me Wiedermann, G. [Kāohi ʻana i ka maʻi diarrhea o ka mea hele me Saccharomyces boulardii. Nā hualoaʻa o kahi placebo kāohi ʻia ka hoʻopaʻa makapō makapō]. Fortschr.Med 3-30-1993; 111: 152-156. Nānā kiʻi ʻole.
  64. Tempe, J. D., Steidel, A. L., Blehaut, H., Hasselmann, M., Lutun, P., a me Maurier, F.. Sem.Hop. 5-5-1983; 59: 1409-1412. Nānā kiʻi ʻole.
  65. Chapoy, P. [Hoʻomaʻamaʻa i ka maʻi pēpē nui: ka hoʻāʻo ʻana o Saccharomyces boulardii]. Ann Pediatr. (Paris) 1985; 32: 561-563. Nānā kiʻi ʻole.
  66. Kimmey, M. B., Elmer, G. W., Surawicz, C. M., a me McFarland, L. V. Kāohi ʻana i nā kū hou ʻana o Clostridium difficile colitis me Saccharomyces boulardii. ʻO Dig.Dis Sci 1990; 35: 897-901. Nānā kiʻi ʻole.
  67. Saint-Marc, T., Rossello-Prats, L., a me Touraine, J. L. [Ka hoʻokō ʻana o Saccharomyces boulardii i ka mālama ʻana i ka maʻi diarrhea i ka maʻi AIDS]. Ann Med Interne (Paris) 1991; 142: 64-65. Nānā kiʻi ʻole.
  68. Duman, DG, Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., ais, F., Vural, T., Sandkci, M., Isksal, F., Simsek, I., Soyturk , M., Arslan, S., Sivri, B., Soykan, I., Temizkan, A., Bessk, F., Kaymakoglu, S., a me Kalayc, C. Ka hoʻokō ʻana a me ka palekana o Saccharomyces boulardii i ka pale ʻana i ka lāʻau antibiotic- pili pākī ma muli o Helicobacterpylori eradication. Eur J Gastroenterol.Hepatol. 2005; 17: 1357-1361. Nānā kiʻi ʻole.
  69. Surawicz, C. M. Hoʻomaʻamaʻa i ka Clostridium difficile-pili maʻi. ʻO Nat Clin Practice. Gastroenterol. Hepatol. 2004; 1: 32-38. Nānā kiʻi ʻole.
  70. Kurugol, Z. a me Koturoglu, G. Nā hopena o Saccharomyces boulardii i nā keiki me ka nui o ka diarrhea. ʻO Acta Paediatr. 2005; 94: 44-47. Nānā kiʻi ʻole.
  71. ʻO Kotowska, M., Albrecht, P., a me Szajewska, H. Saccharomyces boulardii i ka pale ʻana i ka maʻi diarrhea e pili ana i nā antibiotic i nā keiki Aliment.Pharmacol.Ther. 3-1-2005; 21: 583-590. Nānā kiʻi ʻole.
  72. Cherifi, S., Robberecht, J., a me Miendje, Y. Saccharomyces cerevisiae fungemia i kahi mea maʻi me ka Clostridium difficile colitis. ʻO Acta Clin Belg. 2004; 59: 223-224. Nānā kiʻi ʻole.
  73. Erdeve, O., Tiras, U., a me Dallar, Y. ʻO ka hopena probiotic o Saccharomyces boulardii i kahi makahiki pediatric. J Trop.Pediatr. 2004; 50: 234-236. Nānā kiʻi ʻole.
  74. Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., a me Petrochilou, V. Ke komo nei i ka hānai ʻana i nā pēpē mua me Saccharomyces boulardii. ʻO Hum.Dev. 2003; 74: 89-96. Nānā kiʻi ʻole.
  75. Gaon, D., Garcia, H., Winter, L., Rodriguez, N., Quintas, R., Gonzalez, S. N., a me Oliver, G. Ka hopena o nā ʻano Lactobacillus a me Saccharomyces boulardii i ka hoʻomau mau o ka maʻi diarrhea i nā keiki. ʻO Medicina (B Aires) 2003; 63: 293-298. Nānā kiʻi ʻole.
  76. Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., a me Shafaghi, A. Ka maikaʻi o ka saccharomyces boulardii me nā antibiotic i loko o ka amoebiasis. Honua J Gastroenterol. 2003; 9: 1832-1833. Nānā kiʻi ʻole.
  77. Riquelme, A. J., Calvo, M. A., Guzman, A.M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., a me Labarca, J. A. Saccharomyces cerevisiae fungemia ma hope o Saccharomyces boulardii lapaʻau i nā mea maʻi immunocompromised. ʻO J Clin.Gastroenterol. 2003; 36: 41-43. Nānā kiʻi ʻole.
  78. Cremonini, F., Di Caro, S., Santarelli, L., Gabrielli, M., Candelli, M., Nista, EC, Lupascu, A., Gasbarrini, G., a me Gasbarrini, A. ʻO Probiotics i nā antibiotic-pili pāhoehoe. ʻO Dig.Liver Dis. 2002; 34 Hōʻuluʻulu 2: S78-S80. Nānā kiʻi ʻole.
  79. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., a me Malbrunot, C. ʻEhiku mau hihia o ka fungemia me Saccharomyces boulardii ma ke ʻano koʻikoʻi. nā mea maʻi maʻi. ʻOihana Med Med 2002; 28: 797-801. Nānā kiʻi ʻole.
  80. ʻO Tasteyre, A., Barc, M. C., Karjalainen, T., Bourlioux, P., a me Collignon, A. Kaohi ʻana i ka pili vitro cell of Clostridium difficile na Saccharomyces boulardii. ʻO Microb. Pathog. 2002; 32: 219-225. Nānā kiʻi ʻole.
  81. Shanahan, F. Probiotics i ka maʻi ʻōpū. ʻO Gut 2001; 48: 609. Nānā kiʻi ʻole.
  82. Surawicz, CM, McFarland, LV, Greenberg, RN, Rubin, M., Fekety, R., Mulligan, ME, Garcia, RJ, Brandmarker, S., Bowen, K., Borjal, D., a me Elmer, GW The e ʻimi i kahi lāʻau ʻoi aku ka maikaʻi no ka maʻi Clostridium difficile hou: hoʻohana i ka vancomycin dosis kiʻekiʻe i hui pū ʻia me Saccharomyces boulardii. ʻO Clin.Infect. 2000; 31: 1012-1017. Nānā kiʻi ʻole.
  83. Johnston BC, Ma SSY, Goldenberg JZ, et al. ʻO Probiotics no ka pale ʻana o Clostridium difficile-pili diarrhea. Ann Intern Med 2012; 157: 878-8. Nānā kiʻi ʻole.
  84. Munoz P, Bouza E, Cuenca-Estrella M, et al. ʻO Saccharomyces cerevisiae fungemia: kahi maʻi maʻi lele e kū nei. ʻO Clin Infect Dis 2005; 40: 1625-34. Nānā kiʻi ʻole.
  85. Szajewska H, ​​Mrukowicz J. Meta-anamanaʻo: hū ʻole pathogenic Saccharomyces boulardii i ka pale ʻana i ka maʻi palaho e pili ana i nā antibiotic. Aliment Pharmacol Ther 2005; 22: 365-72. Nānā kiʻi ʻole.
  86. Hiki iā M, Besirbellioglu BA, Avci IY, et al. ʻO Prophylactic Saccharomyces boulardii i ka pale ʻana i ka maʻi diarrhea e pili ana i nā antibiotic: ʻO kahi noiʻi prospective. Med Sci Monit 2006; 12: PI19-22. Nānā kiʻi ʻole.
  87. Guslandi M, Giollo P, Testoni PA. ʻO kahi hoʻokolohua hoʻokolohua o Saccharomyces boulardii i ka ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-8. Nānā kiʻi ʻole.
  88. ʻO Guslandi M, Mezzi G, ʻo Sorghi M, ʻo Testoni PA. ʻO Saccharomyces boulardii i ka mālama mālama ʻana i ka maʻi o Crohn. Dig Dis Sci 2000; 45: 1462-4. Nānā kiʻi ʻole.
  89. McFarland LV. Meta-Ka Ikepili o nā probiotics no ka pale ʻana i nā maʻi ʻalopiki e pili ana i ka maʻi diarrhea a me ka mālama ʻana i ka maʻi Clostridium difficile. 'Am J Gastroenterol 2006; 101: 812-22. Nānā kiʻi ʻole.
  90. Marteau P, Seksik P. Ke ahonui o nā probiotics a me nā prebiotics. ʻO J Clin Gastroenterol 2004; 38: S67-9. Nānā kiʻi ʻole.
  91. Borriello SP, Hammes WP, Holzapfel W, et al. Ka palekana o nā probiotics i loaʻa ka lactobacilli a i ʻole bifidobacteria. ʻO Clin Infect Dis 2003; 36: 775-80. Nānā kiʻi ʻole.
  92. Cremonini F, Di Caro S, Covino M, et al. Ka hopena o nā hoʻomākaukau probiotic ʻokoʻa ma nā hopena ʻē aʻe e pili ana i ka anti-helobobacter pylori therapy: kahi hui like, ʻekolu mau makapō, kahi noiʻi ʻia me kahi placebo. 'Am J Gastroenterol 2002; 97: 2744-9. Nānā kiʻi ʻole.
  93. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics i ka pale ʻana i ka maʻi palahā e pili ana i nā antibiotic: meta-analysis. BMJ 2002; 324: 1361. Nānā kiʻi ʻole.
  94. ʻO Muller J, Remus N, Harms KH. Ke aʻo mycoserological o ka mālama ʻana i nā mea maʻi cystic fibrosis pediatric me Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995; 38: 119-23. Nānā kiʻi ʻole.
  95. ʻO Plein K, Hotz J. Nā hopena Therapyutic o Saccharomyces boulardii ma nā hōʻailona koena mālie i kahi pae paʻa o ka maʻi o Crohn me ke ʻano kūikawā i ka maʻi diarrhea mau - kahi papa pailaka. Z Gastroenterol 1993; 31: 129-34. Nānā kiʻi ʻole.
  96. Hennequin C, Thierry A, Richard GF, a me al. ʻO ke kikokiko ʻana ʻo microsatellite ma ke ʻano he pono hana hou no ka ʻike ʻana i nā ʻano Sacreccyces cerevisiae. ʻO J Clin Microbiol 2001; 39: 551-9. Nānā kiʻi ʻole.
  97. ʻO Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia i kahi mea maʻi neutropenic i mālama ʻia me Saccharomyces boulardii. Kākoʻo i ka maʻi maʻi maʻi maʻi maʻi 2000; 8: 504-5. Nānā kiʻi ʻole.
  98. Weber G, Adamczyk A, Freytag S. [Hoʻomaʻamaʻa ʻana i ka huehue me kahi hoʻomākaukau hū]. Fortschr Med 1989; 107: 563-6. Nānā kiʻi ʻole.
  99. Lewis SJ, Freedman AR. ʻO ka ʻatikala nānā: ka hoʻohana ʻana o nā mea ola biotherapeutic i ka pale a me ka mālama ʻana i ka maʻi gastrointestinal. Aliment Pharmacol Ther 1998; 12: 807-22. Nānā kiʻi ʻole.
  100. Krammer M, Karbach U. Antidiarrheal hana o ka hū Saccharomyces boulardii i kaʻiole liʻiliʻi a me ka ʻōpū nui e ka hoʻonāukiuki ʻana i ka lawe ʻana o chloride. Z Gastroenterol 1993; 31: 73-7.
  101. ʻO Czerucka D, Roux I, Rampal P. Saccharomyces boulardii ke kāohi i ka adagosine interagag secretagogue 3 ', 5'-cyclic monophosphate induction i nā ʻōpū o nā ʻōpū. ʻO Gastroenterol 1994; 106: 65-72. Nānā kiʻi ʻole.
  102. Elmer GW, McFarland LV, Surawicz CM, et al. ʻO ka hana a Saccharomyces boulardii i nā maʻi maʻi Clostridium difficile hou. Aliment Pharmacol Ther 1999; 13: 1663-8. Nānā kiʻi ʻole.
  103. Fredenucci I, Chomarat M, Boucaud C, et al. ʻO Saccharomyces boulardii fungemia i ka mea maʻi e loaʻa ana i ka lāʻau ultra-levure. ʻOhana Infect Dis 1998; 27: 222-3. Nānā kiʻi ʻole.
  104. ʻO Pletinex M, Legein J, Vandenplas Y. Fungemia me Saccharomyces boulardii i kahi kaikamahine 1 mau makahiki me ka pākī lōʻihi. ʻO J Pediatr Gastroenterol Nutr 1995; 21: 113-5. Nānā kiʻi ʻole.
  105. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii no Clostridium difficile-pili enteropathies i nā pēpē. ʻO J Pediatr Gastroenterol Nutr 1993; 16: 419-25. Nānā kiʻi ʻole.
  106. Surawicz CM, Elmer GW, Speelman P, et al. Kāohi ʻia o ka diarrhea pili antibiotic e Saccharomyces boulardii: kahi noiʻi prospective. ʻO Gastroenterology 1989; 96: 981-8. Nānā kiʻi ʻole.
  107. Surawicz CM, McFarland LV, Elmer G, et al. ʻO ka mālama ʻana i ka colitis clostridium difficile hou me ka vancomycin a me Saccharomyces boulardii. 'Am J Gastroenterol 1989; 84: 1285-7. Nānā kiʻi ʻole.
  108. McFarland LV, Surawicz CM, Greenberg RN, a me al. Kāohi ʻia o ka diarrhea pili beta-lactam e Saccharomyces boulardii i hoʻohālikelike ʻia me placebo. 'Am J Gastroenterol 1995; 90: 439-48. Nānā kiʻi ʻole.
  109. McFarland LV, Surawicz CM, Greenberg RN, a me al. ʻO kahi hoʻokolohua placebo-kāohi ʻia o Saccharomyces boulardii i hui pū ʻia me nā antibiotic maʻamau no ka maʻi Clostridium difficile. JAMA 1994; 271: 1913-8. Nānā kiʻi ʻole.
  110. ʻO Elmer GW, ʻo McFarland LV. ʻO ka ʻōlelo e pili ana i ka loaʻa ʻole o ka hopena therapeutic o Saccharomyces boulardii i ka pale ʻana i ka maʻi diarrhea pili i nā antibiotic i nā mea maʻi ʻelemakule. ʻO J Infect 1998; 37: 307-8. Nānā kiʻi ʻole.
  111. ʻO Lewis SJ, ʻO Potts LF, ʻo Barry RE. ʻO ka nele o ka hopena therapeutic o Saccharomyces boulardii i ka pale ʻana i nā maʻi maʻi e pili ana i ka lāʻau antibiotic i nā mea maʻi ʻelemakule. ʻO J Infect 1998; 36: 171-4. Nānā kiʻi ʻole.
  112. Bleichner G, Blehaut H, Mentec H, et al. Pale Saccharomyces boulardii pale i ka maʻi palahēhē i nā mea maʻi puhi maʻi maʻi nui. Kauka Lapaʻau Med 1997; 23: 517-23. Nānā kiʻi ʻole.
  113. Castagliuolo I, Riegler MF, Valenick L, et al. Hōʻalo ka Saccharomyces boulardii protease i nā hopena o ka clostridium difficile toxins A a me B i ka mucosa colonic kanaka. ʻO ka maʻi a me ka pale ʻana 1999; 67: 302-7. Nānā kiʻi ʻole.
  114. Saavedra J. Probiotics a me ka maʻi diarrhea infectious. 'Am J Gastroenterol 2000; 95: S16-8. Nānā kiʻi ʻole.
  115. McFarland LV. ʻAʻole ʻo Saccharomyces boulardii ʻo Saccharomyces cerevisiae. ʻO Clin Infect Dis 1996; 22: 200-1. Nānā kiʻi ʻole.
  116. McCullough MJ, Clemons KV, McCusker JH, Stevens DA. ʻIke ʻike ʻike a me nā ʻano virulence o Saccharomyces boulardii (nom. Inval.). ʻO J Clin Microbiol 1998; 36: 2613-7. Nānā kiʻi ʻole.
  117. Niault M, Thomas F, Prost J, et al. ʻO Fungemia ma muli o nā lāhui Saccharomyces i kahi mea maʻi i mālama ʻia me ka enteral Saccharomyces boulardii. ʻOhana Infect Dis 1999; 28: 930. Nānā kiʻi ʻole.
  118. ʻO Bassetti S, Frei R, Zimmerli W. Fungemia me Saccharomyces cerevisiae ma hope o ka mālama ʻana me Saccharomyces boulardii. 'Am J Med 1998; 105: 71-2. Nānā kiʻi ʻole.
  119. ʻO Scarpignato C, Rampal P. Kāohi a me ka mālama ʻana i ka maʻi diarrhea o ka mea huakaʻi. Chemotherapy 1995; 41: 48-81. Nānā kiʻi ʻole.
Nānā hope - 11/10/2020

Nā Hale HōʻIkeʻIke Nui

ʻO Coronavirus i nā keiki: nā ʻōuli, ka mālama ʻana a i ka wā hea e hele ai i ka haukapila
Ola Kino

ʻO Coronavirus i nā keiki: nā ʻōuli, ka mālama ʻana a i ka wā hea e hele ai i ka haukapila

ʻOiai ʻoi aku ka liʻiliʻi o ka pinepine ma mua o ka poʻe mākua, hiki i nā keiki ke hoʻomohala i ka maʻi me ka coronaviru hou, COVID-19. Eia nō naʻe, ʻoi aku ka liʻiliʻi o nā ʻōuli, no ka mea ʻo nā maʻ...
Victoza e lilo i kaupaona: hana maoli ia?
Ola Kino

Victoza e lilo i kaupaona: hana maoli ia?

ʻO Victoza kahi lāʻau i kaulana loa e hōʻeleu i ke kaʻina hana kaumaha. Eia nō naʻe, ʻae wale ʻia kēia hoʻoponopono e ANVI A no ka mālama ʻana i ka maʻi diabete type 2, a ʻaʻole ʻike ʻia e kōkua iā ʻo...